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Abstract
Purpose To address the possible association between the use of metformin, other forms of antidiabetic medication (ADM) 
and statins with the incidence of breast cancer in women with type 2 diabetes (T2D).
Methods Data were collected from a Finnish nationwide diabetes database (FinDM). The study cohort consisted of women 
diagnosed with T2D in 1996–2011 in Finland. In full-cohort analysis, Poisson regression was used to estimate hazard ratios 
(HRs) in relation to use of metformin, insulin, other forms of oral ADM and statins. In nested case–control analysis, up to 
20 controls were matched for age and duration of diabetes to each case of breast cancer. Conditional logistic regression was 
used to estimate HRs in relation to medication use and cumulative use of different forms of ADM, and statins.
Results 2300 women were diagnosed with breast cancer during follow-up. No difference in breast cancer incidence was 
observed between metformin users [HR 1.02, 95% confidence interval (CI) 0.93–1.11] or statin users (HR 0.97, 95% CI 
0.89–1.05) compared with non-users. In nested case–control analysis the results were similar. Use of insulin (HR 1.18, 95% 
CI 1.03–1.36) was associated with a slightly increased incidence of breast cancer.
Conclusions No evidence of an association between the use of metformin or statins and the incidence of breast cancer in 
women with T2D was found. Among insulin users, a slightly higher incidence of breast cancer was observed.
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ICD-O-3  International classification of diseases for 
oncology-3rd edition
mTOR  Mammalian target of rapamycin
T2D  Type 2 diabetes
Introduction
Breast cancer is globally the most common cancer among 
females in both developed and developing countries [1]. 
Among all cancer deaths in women, 15% are caused by dif-
ferent types of breast cancer. Several risk factors of breast 
cancer have been identified, including age, early menarche, 
late menopause, nulliparity, use of oral contraceptives, hor-
mone replacement therapy, family history and obesity [2]. 
People with type 2 diabetes (T2D) also have a higher risk of 
developing breast cancer [3, 4].
Metformin is commonly used as first-line oral medication 
for T2D. Over the years, it has been suggested that met-
formin may decrease breast cancer risk [5], but on the basis 
of a meta-analysis, there is insufficient evidence to support 
this hypothesis [6]. Many preclinical studies have shown 
anticancer effects of metformin in breast cancer and also in 
other types of cancer [7–9]. The insulin/insulin-like growth 
factor-1 signalling pathway and the adenosine mono-phos-
phate-activated protein kinase (AMPK) pathway are known 
to be related pathways involved in cancer growth. AMPK 
negatively regulates the mTOR (mammalian target of rapa-
mycin) signalling pathway, resulting in inhibition of cancer 
proliferation and growth [7, 10]. The exact mechanisms are 
not yet known. Furthermore, it has been suggested that the 
use of glargine (a long-acting insulin analogue that is used 
in patients with diabetes) is associated with an increased 
incidence of breast cancer [11].
Statins, i.e. 3-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) reductase inhibitors, are some of the most 
commonly used cholesterol-lowering drugs in the world. 
Reducing levels of mevalonate with statins are associated 
with apoptosis of cancer cells [12, 13]. Lipophilic statins 
seem to reduce tumour-cell proliferation and survival in vitro 
[14]. However, in a meta-analysis, the association between 
statin use and breast cancer incidence was not confirmed in 
the general population, although women with T2D were not 
assessed separately in this study [15].
In this register-based, cohort and nested case–control 
study, we enriched the evidence base concerning the asso-
ciation between the use of metformin, other types of ADM, 
and statins, with the incidence of breast cancer in women 
with T2D. By virtue of the large and comprehensive Finnish 
nationwide registers available to us, some of the pitfalls in 
previous studies could be overcome in this one.
Patients and methods
In this article, we follow STROBE guidelines for reporting 
observational studies [16].
Data sources and study population
A Finnish diabetes database (FinDM) has been created for 
epidemiological monitoring of diabetes in Finland [17]. This 
database consists of data on patients with diabetes, com-
bining information from different registers in Finland: the 
Special Refund Entitlement Register and the Prescription 
Register, which are maintained by the Social Insurance Insti-
tution, The Care Register for Health Care and the Hospital 
Discharge Register from the National Institute for Health and 
Welfare, and the Causes of Death Register from Statistics 
Finland. The Special Refund Entitlement Register and the 
Prescription Register include information about purchases 
of ADM and statins since 1994, making it possible to accu-
rately track the use of these medications. The Hospital Dis-
charge Register and the Register for Health Care include 
diagnoses from hospital records since 1969 for inpatients, 
and since 1998 for outpatients, too. Patients with diabetes 
are entered in the register on the basis of diabetes diagnosis 
in hospital records or by receiving reimbursement for ADM. 
In some cases, the duration of diabetes may be longer than 
indicated in the register, as FinDM does not contain informa-
tion on earlier diet-controlled diabetes followed in an out-
patient primary-care setting. The classification of patients 
in the register to type 1 and type 2 diabetes was primarily 
based on the ADM used as first-line treatment. Comparison 
of data from FinDM against a local diabetes register cover-
ing the Helsinki region has shown good coverage of diabetic 
persons in the nationwide register [18].
The FinDM data were linked to the files of the Finnish 
Cancer Registry, which contain all cancer cases diagnosed 
in Finland since 1953 [19]. Data on mortality were obtained 
from Statistics Finland. Data linkage between various regis-
ters was carried out on the basis of the personal identifica-
tion codes unique to each resident of Finland.
The FinDM dataset contains data on approximately 
240,000 women with T2D. In this study, we included 
women who were at least 40 years old and were newly 
diagnosed with T2D between the 1st of January 1996 and 
the 31st of December 2011. Women with prior breast can-
cer (diagnosed before the start of individual follow-up) 
and women with T2D who were diagnosed before 1996, 
and also women whose eligibility criteria would have been 
met only after 2011, were excluded. The final number of 
women with T2D in the cohort was about 140,000 (see 
Fig. 1).
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Four indicators were defined for medication expo-
sure: ever use of (1) metformin, (2) other types of oral 
ADM, (3) insulin and (4) statins. Details on Anatomical 
Therapeutic Chemical (ATC) codes of oral ADM and 
statins are listed in Supplementary Table. Exposure to 
a given medication was considered to begin a full year 
after its purchase date in order to avoid reverse causality 
problems. In the full-cohort analyses and in the nested 
case–control analyses, the study subjects were catego-
rized as exposed to the drug from this moment onwards 
throughout the follow-up time. Additionally, cumulative 
use of metformin and statins, other forms of oral ADM 
and insulin were estimated by using defined daily doses 
(DDDs) purchased during the entire follow-up period (Jan. 
1996–Dec. 2011).
Follow-up of each patient started 365 days after diagno-
sis of T2D. It ended on the date of breast cancer diagnosis, 
death, or the end of study period (the 31st of December 
2011), whichever occurred earliest.
A nested case–control study within the cohort was con-
ducted to evaluate the association between breast cancer 
and the cumulative use of the types of medication under 
study. This design, versus a full-cohort design, enables 
more straightforward calculation of the number of defined 
daily doses of medication used by each woman prior to 
their respective index date. For each case subject, up 
to 20 controls were selected without replacement from 
those women in the cohort who were alive and at risk of 
breast cancer at the date of breast cancer diagnosis of the 
case, and who were also matched for both age (date of 
birth ± 182 days) and duration of diabetes (± 182 days).
Statistical analysis
In the full-cohort analysis, a Poisson regression model [20] 
was used to estimate hazard ratios (HRs) with 95% confi-
dence intervals (95% CIs) of the incidence of breast cancer 
in relation to use of metformin, other forms of ADM and 
statins. In addition, the effects of current age and duration 
of T2D were assumed to obey a piecewise constant haz-
ards pattern over chosen intervals of these two time scales. 
Age was split into 5-year intervals from 40 to 44 years to 
85–89 years plus one more interval covering ages over 90 
years, and duration of type 2 diabetes into intervals that 
are shown in Table 1. In the nested case–control analysis, 
conditional logistic regression [21] was utilized to estimate 
HRs with 95% CIs in relation to the use of different forms 
of ADM and statins. Cumulative doses were categorized 
according to tertiles of the total amounts of DDDs used. The 
register data were pre-processed using SAS/STAT software 
version 9.4 of the SAS System for Windows. Subsequent 
data transformations and statistical analysis were performed 
in R environment version 3.3.2 [22].
Results
Our final study cohort consisted of 141,194 women diag-
nosed with T2D between 1996 and 2011 and at least 
365 days after diabetes diagnosis (Fig. 1). The total follow-
up covered 768,633 person-years at risk (Table 1), the mean 
follow-up time being 5.4 years. During the study period, 
2300 women were diagnosed with breast cancer for the first 
time (Table 1). Of these, 72% were ductal breast cancer 
cases and 17% had lobular histology.
Fig. 1  Flow chart showing how 
the cohort was found Women with type 2 diabetes in the database
N=244,322
Death before start of follow-up
N=7,314
Breast cancer prior to start of follow-up
N=8,212
Diabetes diagnosed prior to 1996
N=69,960
Final cohort 
N=141,194
Start of follow-up criteria met only after 2011
N=17,642
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The age-specific incidence rate (cases/100,000 person-
years) of breast cancer was highest in the group of women 
aged 60–69 years (Table 1). The incidence of breast can-
cer was higher in patients whose duration of diabetes was 
over 8 years, compared with those with a shorter duration 
of the disease. Of the 2300 diabetic women diagnosed with 
breast cancer, 65.8% were metformin ever-users, and 49.4% 
were users of other types of oral ADM. A minority (13.2%) 
used insulin, and 17.9% had no ADM. Just over half of the 
patients (51%) were statin users, of whom 71% used simvas-
tatin and 27% atorvastatin (Supplementary File 1).
In the full-cohort Poisson regression model (Table 2), 
no association was found between the incidence of breast 
cancer and use of metformin at any time (adjusted HR 1.02, 
95% CI 0.93–1.11). However, use of insulin at any time 
was observed to be weakly associated with an increased 
incidence of breast cancer (HR 1.18, 95% CI 1.03–1.35). 
No association between the incidence of breast cancer and 
use of statins at any time was discerned (HR 0.97, 95% CI 
0.89–1.05). The results of the nested case–control analy-
sis were practically the same as regards use of the different 
types of medication under study (Table 2).
Apart from a slightly lower incidence among women 
whose cumulative DDD of metformin was at least 1200, 
there was no evidence of consistent dependence of the inci-
dence of breast cancer on the cumulative use of metformin, 
other forms of oral ADM, or statins. A positive trend in 
breast cancer risk was observed with increasing cumulative 
use of insulin, the estimate being 1.46 (95% CI 1.19–1.81) 
Table 1  Distribution of person-
years at risk, numbers of cases 
and matched controls, and 
incidence rates of breast cancer 
by age, duration of diabetes and 
ever use of ADM and statins
Variable Value Person-years in 
cohort
Cases (%) Controls (%) Incidence (per 
100,000 person-
years)
Age (years)
40–49 48,365 59 (2.6) 1231 (2.7) 122.0
50–59 134,663 346 (15.0) 6903 (15.1) 256.9
60–69 205,392 715 (31.1) 14,229 (31.1) 348.1
70–79 219,352 671 (29.2) 13,496 (29.5) 305.9
80–89 141,150 448 (19.5) 8828 (19.3) 317.4
90–106 19,739 61 (2.7) 1068 (2.3) 309.0
Duration of diabetes (years)
1–< 3 245,962 717 (31.2) 14,252 (31.1) 291.5
3–< 5 180,562 522 (22.7) 10,290 (22.5) 289.1
5–< 8 182,027 557 (24.2) 11,238 (24.6) 306.0
8–< 16 160,082 504 (21.9) 9975 (21.8) 314.8
Metformin use
Ever 502,076 1514 (65.8) 30,588 (66.9) 301.5
Never 266,557 786 (34.2) 15,167 (33.1) 294.9
Other oral antidiabetic medication use
Ever 376,233 1136 (49.4) 22,595 (49.4) 301.9
Never 392,400 1164 (50.6) 23,160 (50.6) 296.6
Insulin use
Ever 90,162 304 (13.2) 5399 (11.8) 337.2
Never 678,471 1996 (86.8) 40,356 (88.2) 294.2
No antidiabetic medication 145,612 412 (17.9) 8103 (17.7) 282.9
Statin use
Ever 384,679 1165 (50.7) 23,935 (52.3) 302.8
Never 383,954 1135 (49.3) 21,820 (47.7) 295.6
Total 768,633 2300 (100) 45,755 (100) 299.2
Table 2  Adjusted estimates of hazard ratios (HRs) with 95% confi-
dence intervals (CIs) for the association between breast cancer inci-
dence and ever use of metformin, insulin, other types of oral ADM, 
and statins compared with no use of these forms of medication at any 
time
u unadjusted, a adjusted, full-cohort Poisson regression, c adjusted, 
case–control conditional logistic regression
Ever use HR (u) HR (a) HR (c)
Metformin 1.02 1.02 (0.93–1.11) 0.94 (0.86–1.04)
Insulin 1.15 1.18 (1.03–1.35) 1.18 (1.03–1.36)
Other oral antidia-
betic medication
1.02 0.95 (0.87–1.04) 0.98 (0.89–1.08)
Statin 1.02 0.97 (0.89–1.05) 0.93 (0.85–1.02)
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for the amount of DDDs being 1200 or more when compared 
with no use at any time (Fig. 2).
There was no evidence of an interaction effect of met-
formin and statin use in the case–control analysis, the inter-
action HR being 1.03 (95% CI 0.86–1.24).
Discussion
In our study, no evidence of any association between met-
formin use and the incidence of breast cancer in either the 
full-cohort analysis or in the case–control analysis was found 
in women with T2D. A similar result was observed in con-
nection with use of other forms of ADM and statins. How-
ever, insulin use was found to be associated with a slightly 
increased incidence of breast cancer in the full cohort as 
well as in the case–control analysis. Furthermore, increasing 
cumulative use of insulin was observed to be positively asso-
ciated with the risk of breast cancer in a monotonic manner.
Several epidemiological studies on breast cancer inci-
dence and metformin use have been published before. In 
some of them, metformin use seems to be related to a low-
ered breast cancer incidence [23–26], at least in connection 
with long-term metformin use [27, 28]. However, similarly 
to our findings, most of these studies have not revealed any 
association between metformin use and the incidence of 
breast cancer [29–34]. In one study, the use of metformin 
was reported to be associated with an increased risk of breast 
cancer among insulin users [35]. In our study also, insulin 
use was associated with an increased incidence of breast 
cancer. Our findings are similar to those of some previous 
studies [36]. However, the increased risk of breast cancer 
has mainly been associated with long-term use of the insu-
lin analogue glargine [11]. In our study, we did not analyse 
insulin types separately.
There are also several reviews and meta-analyses in which 
it has been concluded that statin use is not associated with 
the risk of breast cancer [37–42]. In a few studies, lipophilic 
statins, such as atorvastatin and simvastatin, have appeared 
to be associated with a decreased incidence of breast cancer 
[43]. In contrast to our study, the populations in these studies 
have not been limited to women with T2D.
Major strengths of our study are the large sample size 
and the availability of reliable and comprehensive national 
registers. The patients’ details are entered into the diabetes 
register at the time of the first reimbursement for any form of 
Fig. 2  Estimated hazard ratios of breast cancer by cumulative doses of different forms of ADM and statins, adjusted for age, duration of diabetes 
and use of other medication
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ADM, and thus the data in the register concerning the date 
of diagnosis of diabetes are considered to be accurate. To our 
knowledge, this study is the first one in which the associa-
tion between statin use and the incidence of breast cancer 
in women with T2D has been explored. Also, our study has 
involved one of the largest study populations in addressing 
the relationship between ADM and breast cancer incidence.
A weakness of our study is that the FinDM database 
includes only information available in the registers. There-
fore, we lack information on some known risk factors as 
regards the development of breast cancer, including body 
mass index (BMI), parity, use of contraceptives, use of hor-
mone replacement therapy and family history. However, it 
is not known how these risk factors (apart from BMI) differ 
within ADM and statin users. Obesity is a common risk 
factor of both T2D and breast cancer. In the United King-
dom and the Netherlands, for example, metformin users have 
been found to have a higher BMI [44, 45]. Some review 
articles have described BMI as a time-dependent confounder 
[46]. Although the data on purchased medication are accu-
rate, we could not cover the drugs dispensed in hospitals 
and outpatient clinics. However, only a small proportion of 
women with T2D are treated for long-term periods in health-
care facilities.
In conclusion, we found no association between met-
formin or statin use and the incidence of breast cancer in 
women with T2D. However, insulin use (especially cumu-
lative use) was found to be associated with an increased 
incidence of breast cancer.
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